Age-Stratified Outcome in Treatment of Left Main Coronary Artery Stenosis: A NOBLE Trial Substudy.


Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
2021
Historique:
received: 12 12 2020
accepted: 26 01 2021
pubmed: 14 4 2021
medline: 1 9 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

In the treatment of left main coronary artery (LMCA) disease, patients' age may affect the clinical outcome after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). This study stratified the clinical outcome according to the age of patients treated for LMCA stenosis with PCI or CABG in the Nordic-Baltic-British Left Main Revascularization (NOBLE) study. Patients with LMCA disease were enrolled in 36 centers in northern Europe and randomized 1:1 to treatment by PCI or CABG. Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST elevation myocardial infarction. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCEs), a composite of all-cause mortality, nonprocedural myocardial infarction, any repeat coronary revascularization, and stroke. Age-stratified analysis was performed for the groups younger and older than 67 years and for patients older than 80 years. For patients ≥67 years, the 5-year MACCEs were 35.7 versus 22.3% (hazard ratio [HR] 1.72 [95% confidence interval [CI] 1.27-2.33], p = 0.0004) for PCI versus CABG. The difference in MACCEs was driven by more myocardial infarctions (10.8 vs. 3.8% HR 3.01 [95% CI 1.52-5.96], p = 0.0009) and more repeat revascularizations (19.5 vs. 10.0% HR 2.01 [95% CI 1.29-3.12], p = 0.002). In patients younger than 67 years, MACCE was 20.5 versus 15.3% (HR 1.38 [95% CI 0.93-2.06], p = 0.11 for PCI versus CABG. All-cause mortality was similar after PCI and CABG in both age-groups. On multivariate analysis, age was a predictor of MACCE, along with PCI, diabetes, and SYNTAX score. As the overall NOBLE results show revascularization of LMCA disease, age of 67 years or older was associated with lower 5-year MACCE after CABG compared to PCI. Clinical outcomes were not significantly different in the subgroup younger than 67 years, although no significant interaction was present between age and treatment. Mortality was similar for all subgroups (ClinicalTrials.gov identifier: NCT01496651).

Sections du résumé

BACKGROUND
In the treatment of left main coronary artery (LMCA) disease, patients' age may affect the clinical outcome after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). This study stratified the clinical outcome according to the age of patients treated for LMCA stenosis with PCI or CABG in the Nordic-Baltic-British Left Main Revascularization (NOBLE) study.
METHODS
Patients with LMCA disease were enrolled in 36 centers in northern Europe and randomized 1:1 to treatment by PCI or CABG. Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST elevation myocardial infarction. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCEs), a composite of all-cause mortality, nonprocedural myocardial infarction, any repeat coronary revascularization, and stroke. Age-stratified analysis was performed for the groups younger and older than 67 years and for patients older than 80 years.
RESULTS
For patients ≥67 years, the 5-year MACCEs were 35.7 versus 22.3% (hazard ratio [HR] 1.72 [95% confidence interval [CI] 1.27-2.33], p = 0.0004) for PCI versus CABG. The difference in MACCEs was driven by more myocardial infarctions (10.8 vs. 3.8% HR 3.01 [95% CI 1.52-5.96], p = 0.0009) and more repeat revascularizations (19.5 vs. 10.0% HR 2.01 [95% CI 1.29-3.12], p = 0.002). In patients younger than 67 years, MACCE was 20.5 versus 15.3% (HR 1.38 [95% CI 0.93-2.06], p = 0.11 for PCI versus CABG. All-cause mortality was similar after PCI and CABG in both age-groups. On multivariate analysis, age was a predictor of MACCE, along with PCI, diabetes, and SYNTAX score.
CONCLUSIONS
As the overall NOBLE results show revascularization of LMCA disease, age of 67 years or older was associated with lower 5-year MACCE after CABG compared to PCI. Clinical outcomes were not significantly different in the subgroup younger than 67 years, although no significant interaction was present between age and treatment. Mortality was similar for all subgroups (ClinicalTrials.gov identifier: NCT01496651).

Identifiants

pubmed: 33849035
pii: 000515376
doi: 10.1159/000515376
doi:

Banques de données

ClinicalTrials.gov
['NCT01496651']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-418

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Terje Steigen (T)

Cardiovascular Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
Department of Cardiology, University Hospital of North Norway, Tromsø, Norway.

Niels Ramsing Holm (NR)

Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Truls Myrmel (T)

Cardiovascular Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
Department of Cardiovascular Surgery, University of Northern Norway, Tromsø, Norway.

Petter C Endresen (PC)

Department of Cardiovascular Surgery, University of Northern Norway, Tromsø, Norway.

Thor Trovik (T)

Department of Cardiology, University Hospital of North Norway, Tromsø, Norway.

Timo Mäkikallio (T)

Department of Cardiology, Oulu University Hospital, Oulu, Finland.

Mitchell Lindsay (M)

Department of Cardiology, Golden Jubilee National Hospital, Clydebank, United Kingdom.

Mark S Spence (MS)

Belfast Heart Centre, Belfast Trust, Belfast, United Kingdom.

Andrejs Erglis (A)

Latvia Centre of Cardiology, Paul Stradins Clinical Hospital, Riga, Latvia.

Ian B A Menown (IBA)

Craigavon Cardiac Centre, Craigavon, United Kingdom.

Indulis Kumsars (I)

Latvia Centre of Cardiology, Paul Stradins Clinical Hospital, Riga, Latvia.

Thomas Kellerth (T)

Department of Cardiology, Örebro University Hospital, Örebro, Sweden.

Giedrius Davidavičius (G)

Department of Cardiology, Vilnius University Hospital, Vilnius, Lithuania.

Rikard Linder (R)

Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.

Vesa Anttila (V)

Department of Cardiac Surgery, Oulu University Hospital, Oulu, Finland.

Lone Juul Hune Mogensen (L)

Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Per Hostrup Nielsen (P)

Department of Cardiac Surgery, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Alastair N J Graham (ANJ)

Belfast Heart Centre, Belfast Trust, Belfast, United Kingdom.

David Hildick-Smith (D)

Sussex Cardiac Centre, Brighton and Sussex University Hospital, Brighton, United Kingdom.

Leif Thuesen (L)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Evald Høj Christiansen (EH)

Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH